Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609212 | 1.00 | HIF1A (0.56) | HIF1ASLC29A1PNPLMNATP53 | |
| SCHEMBL15171798 | 1.00 | HIF1A (0.56) | HIF1ASLC29A1PNPLMNATP53 | |
| SCHEMBL26647666 | 1.00 | HIF1A (0.56) | HIF1ASLC29A1PNPLMNATP53 | |
| SCHEMBL13239710 | 0.92 | HIF1A (0.48) | HIF1A | |
| SCHEMBL15165612 | 0.86 | HIF1A (0.41) | HIF1ASLC29A1 | |
| SCHEMBL13265482 | 0.85 | HIF1A (0.42) | HIF1ASLC29A1 | |
| SCHEMBL13239659 | 0.84 | HIF1A (0.39) | HIF1ASLC29A1 | |
| SCHEMBL13265449 | 0.84 | SLC29A1 (0.64) | SLC29A1LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL13239670 | 0.84 | SLC29A1 (0.64) | SLC29A1LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL18486376 | 0.82 | TYMP (0.52) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | HIF1A 3959/4885SLC29A1 19/4885PNP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.